Project Grant R01FD008196
Award Date
9/20/24
Completion Date
8/31/28
Dollars Obligated
$480K
Funding Federal Agency
Office of Medical Products and Tobacco
Awarding Federal Agency
FDA Office of Acquisition and Grant Services
Federal Grant Program
93.103
Assistance Type
Project Grant
Place of Performance
Wayne, PA, USA
Similar Awards
Larix Bioscience LLC received a $245,728 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports the company's research and development of novel therapies for improving lymphatic dysfunction, a complication commonly associated with obesity and diabetes. Specifically, the grant funds the generation and preclinical evaluation of albumin and Fc fusion protein therapeutics targeting adrenomedullin...
This $502,294 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837) aims to integrate advanced biomaterials and targeted delivery of lipid nanoparticles into current lymphedema surgical procedures to enhance lymphangiogenesis and improve treatment outcomes. The key objectives are to: 1) Evaluate lymphangiogenic hydrogels and their capacity to induce lymphangiogenesis and facilitate engraftment...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $116,278 to the University of South Florida to investigate the role of the plasminogen activator (PA) pathway in lymphatic malformations. The key research activities include: Assessing the expression of key PA enzymes and utilizing in vitro zymography to evaluate matrix metalloproteinase (MMP) activation related to lymphatic valve defects...
This $144,362 Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a research project focused on investigating the effectiveness and mechanisms of lymphaticovenous anastomoses (LVA) for treating lymphedema. The research integrates computational modeling with clinical LVA insights to gain a deeper understanding of lymphatic flow dynamics and adaptations in response to this surgical intervention. The project, led by...
The National Cancer Institute (NCI) awarded a $556,684 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Palo Alto Veterans Institute for Research (PAVIR) to develop a bioengineered therapeutic device for the prevention of lymphedema. The objective is to optimize the structural and mechanical properties of a collagen conduit implant to promote lymphatic regeneration and normalize lymph flow, thereby preventing the onset of lymphedema in at-risk cancer patients. As a...
This Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 will provide $463,150 to The Regents of the University of California, San Francisco (UCSF) to establish proof-of-concept for enzyme replacement therapy (ERT) as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndrome (SPLIS), an ultra-rare and often lethal metabolic disorder. The project aims to demonstrate the efficacy of ERT in preserving kidney function and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $508,436 to The University of Texas Southwestern Medical Center to investigate the genetic and environmental factors contributing to the development of complex lymphatic anomalies (CLAs), a group of rare vascular diseases. The research team will use a novel mouse model to test the hypothesis that CLA formation requires both a genetic mutation in lymphatic...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $613,036 to Fibrobiologics LLC for the development of a novel peptide-based therapeutic agent called M10 to treat skin fibrosis associated with systemic sclerosis (scleroderma). The research aims to determine the antifibrotic activity of M10 in primary skin fibroblasts from...
The National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, awarded a $295,923 Project Grant to Kinetiq Therapeutics LLC to conduct preclinical efficacy studies of a subcutaneous enzyme therapy for Fabry disease. The proposed therapy, named BRYSQ, aims to transform the current standard of care by providing a convenient, self-administered treatment that could improve patient quality of life, reduce hospital use, and lower treatment costs compared to the...
This federal Project Grant award of $849,648 from the Food and Drug Administration (FDA) Research program (CFDA 93.103) supports a pilot Phase 2 clinical study to evaluate the safety and efficacy of the dual PI3K + HDAC inhibitor, fimepinostat, for the treatment of Cushing's disease. The study, to be conducted at the University of California, Los Angeles (UCLA), aims to assess the ability of fimepinostat to normalize cortisol levels in 20 patients with de novo, persistent, or recurrent Cushing's...